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The “Classical Endocrinology” is the fas-
cinating world of endocrine glands, their 
specific hormones and their diseases. This 
encapsulates the integration of develop-
mental events such as the proliferation, 
growth, and differentiation of tissues and 
organs and the coordination of many physi-
ological functions, such as metabolism and 
reproduction, by chemical substances syn-
thesized and secreted by specialized cells. 
A modern view of Endocrinology requires, 
in our opinion, a more detailed sight in 
the field not only of endocrine glands and 
their diseases, but also of the multitude 
of organs and cells involved, influenced 
and eventually controlled by large intri-
cate pathways of signaling activated by a 
very heterogeneous group of substances 
targeting a wide spectrum of receptors 
and cells throughout the body. Therefore, 
today “Cancer Endocrinology” necessarily 
means focusing on all endocrine tumors 
from classical ones, such as pituitary, thy-
roid, parathyroid, adrenal, and neuroendo-
crine tumors, to types of cancer in which 
endocrine hormones seem to play a relevant 
role such as breast, prostate, ovaries, colon, 
and liver tumors and probably many others. 
As such Cancer Endocrinology should now 
be of particular interest for experimental, 
preclinical, and clinical researchers. Cancer 
Endocrinology now encompases the follow-
ing issues: identification of a definitive role 
for new laboratory tests and radiological 
techniques in diagnosis; identification of 
specific molecular patterns of tumorigen-
esis, which could allow development of new 
directions in the field of pharmacotherapy 
research; combined treatment with conven-
tional treatment options and new molecules 
in preclinical evaluation; synergy between 
chemotherapy and other anticancer modal-
ities, including radiotherapy, immuno-
therapy, and gene therapy; discovery of new 
biomarkers to predict response or resistance 
to drug treatment or to guide the follow-up 
of treated patients.
Examples of developments in cancer 
endocrinology include the role of soma-
tostatin (SSTR) and dopamine receptors 
(DR) as molecular targets for the treatment 
of patients with pituitary adenomas and 
neuroendocrine tumors: this has received 
great attention and is leading to innovative 
new therapies. The evidence of expression 
of subtypes of SSTR and DR, as well as of 
co-expression of these receptors in tumor 
cells, has increased the development of new 
experimental drugs, including novel ana-
logs, binding to multiple SSTR subtypes, 
as well as hybrid somatostatin–dopamine 
compounds. These advances have opened 
new perspectives for the medical treatment 
of pituitary and neuroendocrine tumors 
poorly responsive to conventional thera-
pies and probably also for the treatment of 
other tumor types. Pasireotide (SOM230), 
a novel somatostatin analog with a pecu-
liar receptor binding that makes this analog 
the closest to native somatostatin, is under 
detailed investigation in Cushing’s disease, 
so far an orphan disease for medical therapy. 
Everolimus, an m-TOR inhibitor, indicated 
for treatment of renal carcinoma, has also 
been demonstrated to have some efficacy for 
patients with neuroendocrine tumors sup-
plementing the medical armamentarium for 
management of these patients. Nonetheless, 
today management of aggressive pituitary 
adenomas still remains a challenging clini-
cal problem: new potential therapies such as 
gene therapy, temozolomide, or a combina-
tion of target therapies are foreseen as future 
strategies for these patients.
Another important endocrine axis to 
be considered in carcinogenesis are repre-
sented by growth factors such as the insu-
lin/insulin-like growth factor-I (IGF I). 
The IGF system mediates growth, differ-
entiation, and developmental processes. 
Clinical conditions associated with high 
levels of insulin (non-insulin-dependent 
diabetes mellitus and hypertriglyceridemia) 
and IGF-I (acromegaly) are related to 
increased risk of neoplasms, and increased 
circulating concentrations of insulin and 
IGF-I are related to a higher risk of colonic 
neoplasia. Deregulation of IGF system 
expression and action is linked to differ-
ent diseases, ranging from growth deficits 
to cancer development. Targeting of the 
IGF axis has emerged in recent years as a 
promising therapeutic approach in can-
cer and other conditions. Rational use of 
IGF-I-induced gene signatures may help to 
identify patients who might benefit from 
IGF axis-directed therapeutic modalities. 
IGF-I-induced gene expression in primary 
breast and lung fibroblasts accurately pre-
dict outcomes in breast and lung cancer 
patients. Further studies to investigate the 
role of IGF-pathway on colorectal, prostatic, 
and breast and lung cancer are required.
Classically modulation of gonadal ster-
oids is used as adjuvant treatment in patients 
with breast and prostate cancers. However, 
hypogonadism (as a consequence of ovar-
ian and testicular blockade) causes insulin 
resistance so that patients would probably 
acquire a secondary cause of tumor relapse 
as discussed above. No data are currently 
available on this matter but it is expected 
that use of insulin-sensitizers (currently 
under investigation) would modify the 
natural history of breast and prostate can-
cer patients treated with the estrogens or 
androgens blockade.
A separate field of investigation relates 
to the so-called “neuroendocrine degenera-
tion” of some cancers, particularly the pros-
tate. The clinical significance and possible 
treatment approach of tumors with such a 
phenotype is still far from being elucidated.
Lastly, considerable preclinical and epi-
demiologic data suggest that vitamin D 
may play a role in the pathogenesis, pro-
gression, and therapy for cancer. The rel-
evance of vitamin D receptor (VDR) gene 
polymorphisms for various types of cancer 
has been widely investigated. It has been 
hypothesized that VDR polymorphisms 
may influence both the risk of cancer 
occurrence and prognosis. However, stud-
ies investigating the associations between 
specific VDR polymorphisms and cancer 
often show controversial results. Data 
indicating an association of VDR poly-
morphisms and cancer risk are relevant for 
breast cancer, prostate cancer, and malig-
nant melanoma. Higher risk of cancer has 
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 multifaceted approach involving genetics, 
cellular and molecular biology, pathophysi-
ology, and oncology would allow a better 
knowledge of endocrine tumor pathogen-
esis and eventually to the development of 
new therapeutic strategies in all the field of 
the “Cancer Endocrinology.”
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through a number of important pathways, 
but the pathway(s) essential to the antitu-
mor activities of vitamin D are unclear. In 
view of the substantial preclinical and epi-
demiologic data supporting the potential 
role of vitamin D in cancer, further studies 
to evaluate the impact of vitamin D replace-
ment on the frequency of cancer and the 
impact of an appropriate dose and schedule 
of treatment are indicated.
The vitamin D and insulin axes are 
also related to the wider argument of the 
nutritional background of cancer, tightly 
linked to the hormonal regulation of cell 
differentiation.
In conclusion, the endocrine system 
seems to be a key to open the full under-
standing of tumoral development. A 
been linked with lower serum vitamin D 
levels. Unfortunately, very limited data are 
available to indicate whether or not giving 
vitamin D supplements reduces the risk 
of cancer. Many preclinical studies indi-
cate that exposing cancer cells or vascular 
endothelial cells derived from tumors, to 
high concentrations of vitamin D could 
reduce progression through the cell cycle, 
induce apoptosis and slow or stop the 
growth of tumors in vivo. Despite these 
observations there are no data indicating 
that one type of cancer is more or less sus-
ceptible to the effects of vitamin D. Vitamin 
D also potentiates the antitumor activity 
of a number of types of cytotoxic antican-
cer agents examined in preclinical mod-
els. Vitamin D analogs initiate signaling 
